PillRx only · Injection, Solution · Intravenous
Florbetaben F 18
Brands: Neuraceq · Florbetaben F-18
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)1492611
US makers1 labelers
Packages1
DEA / ScheduleNone
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
65
Rx · 2026 Q1
65
Units dispensed
2
Quarters · since 2025 Q4
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Lantheus Biosciences Ltd., a Lantheus Company | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Aug 22, 2023RECALLRecall (Class II): Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Int…
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT). — Recalling firm: Sofie Co dba Sofie — Product was released to one facility in VA.